Menu Search
Equities

IDEAYA Biosciences Inc

IDYA:NSQ

IDEAYA Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)30.98
  • Today's Change-1.00 / -3.13%
  • Shares traded540.61k
  • 1 Year change+5.41%
  • Beta0.8326
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy6
Outperform7
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Ideaya Biosciences Inc have a median target of 58.00, with a high estimate of 65.00 and a low estimate of 27.00. The median estimate represents a 87.22% increase from the last price of 30.98.
High109.8%65.00
Med87.2%58.00
Low-12.8%27.00

Earnings history & estimates in USD

On Nov 04, 2024, Ideaya Biosciences Inc reported 3rd quarter 2024 losses of -0.600 per share. This result exceeded the -0.63 consensus loss of the 13 analysts covering the company and under-performed last year's 3rd quarter results by 30.43%.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate-7.88%
Ideaya Biosciences Inc reported annual 2023 losses of -1.96 per share on Feb 20, 2024.
Average growth rate+4.72%
More ▼

Revenue history & estimates in USD

IDEAYA Biosciences, Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 7.88m.
Average growth rate-37.80%
IDEAYA Biosciences, Inc. had revenues for the full year 2023 of 23.39m. This was 54.08% below the prior year's results.
Average growth rate+23.73%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.